Epiandrosterone
1. Identity and Chemical Characterization
1.1 Names and Nomenclature
Epiandrosterone, or isoandrosterone, is also known as 3β-androsterone, 3β-hydroxy-5α-androstan-17-one, or 5α-androstan-3β-ol-17-one, and is a steroid hormone with weak androgenic activity. Its CAS Registry Number is 481-29-8, and its molecular formula is C19H30O2 with a molecular weight of approximately 290.44 g/mol, as established in the NIST WebBook and the Japanese Science and Technology J-GLOBAL database. Other synonyms recorded in the NIST WebBook include D-Epiandrosterone, iso-Androsterone, trans-Androsterone, 3-Epiandrosterone, and 3β-Hydroxyetioallocholan-17-one. In sport and supplement contexts it is colloquially abbreviated as Epi-Andro.
Chemically, epiandrosterone is a 3β-hydroxy steroid that is (5α)-androstane substituted by a β-hydroxy group at position 3 and an oxo group at position 17, as recorded by ChEBI (EMBL-EBI). It is a steroid hormone with weak androgenic activity, derived from 5α-androstane. Androsterone is its 3-alpha isomer, and epiandrosterone is the 3-beta isomer of the same androstane skeleton, a structural distinction with meaningful biological consequences because the two isomers interact differently with receptor systems.
The physical form of epiandrosterone is described by chemical suppliers as a white to off-white crystalline powder. Epiandrosterone is mainly transformed into 17β-hydroxylated derivatives, 7- or 16α-hydroxylated metabolites under NAD(P)H conditions, and 5α-androstane-3,17-dione under NAD(P)+ conditions.
1.2 Relationship to Other Androgens
Epiandrosterone is a steroid hormone with weak androgenic activity and is a metabolite of testosterone and dihydrotestosterone (DHT). It is a dehydroepiandrosterone metabolite and an androgen, and it is a precursor of testosterone and estradiol with hypolipidemic and anabolic activities. As the 17-ketosteroid metabolite of the testosterone precursor DHEA, epiandrosterone was long considered to be merely an inactive end product of DHEA, but may in fact be a physiological effector in its own right.
2. Natural Sources and Occurrence
Epiandrosterone is a naturally occurring steroid hormone and a metabolite of dehydroepiandrosterone (DHEA) in the human body, produced in the adrenal glands, gonads, and brain. It is naturally produced by the enzyme 5α-reductase from the adrenal hormone DHEA. Epiandrosterone can also be produced from the natural steroids androstanediol via 17β-hydroxysteroid dehydrogenase or from androstanedione via 3β-hydroxysteroid dehydrogenase.
It is formed in peripheral tissues, from which it is released into the circulation and is ultimately excreted in the urine. Epiandrosterone is present in normal human urine as a minor constituent; it is a less active 3β-isomer of the androgen androsterone. Epiandrosterone has been shown to naturally occur in most mammals, including pigs. It has also been reported to occur in pine pollen, though this claim, while widely cited in popular sources, requires verification against primary peer-reviewed analytical chemistry studies before it can be treated as definitively established.
3. Historical Discovery and Background
Epiandrosterone was first isolated in 1931 by Adolf Friedrich Johann Butenandt and Kurt Tscherning. They distilled over 17,000 litres of male urine, from which they obtained 50 milligrams of crystalline androsterone (most likely mixed isomers), which was sufficient to establish that the chemical formula was very similar to estrone. The isolation from urine was thus primarily of androsterone, with epiandrosterone recognized as the 3β-epimeric isomer within that crystalline mixture. Butenandt was subsequently awarded the Nobel Prize in Chemistry in 1939 in part for his work on sex hormones.
Epiandrosterone did not have a discrete traditional use history in the way botanical medicines do, because it was not known as an isolable compound before the twentieth century. Its emergence as a dietary supplement ingredient is an entirely modern phenomenon: it was introduced into the sports nutrition market in the United States in the late 1990s and early 2000s as part of the wave of so-called prohormone supplements that followed the Dietary Supplement Health and Education Act of 1994. Epiandrosterone has been used as an anabolic agent, marketed as a dietary supplement and precursor to dihydrotestosterone.
4. Biosynthesis and Endogenous Metabolism
Epiandrosterone sits within the broader cascade of adrenal and gonadal steroidogenesis. DHEA is naturally produced from cholesterol through two cytochrome P450 enzymes: cholesterol is converted to pregnenolone by the enzyme P450 scc (side chain cleavage), and then CYP17A1 converts pregnenolone to 17-hydroxypregnenolone and then to DHEA. From DHEA, epiandrosterone is produced by the enzyme 5α-reductase.
The epiandrosterone is a metabolite of testosterone precursor dehydroepiandrosterone and is produced in peripheral tissues and released into the circulation, then excreted in the urine. Like dehydroepiandrosterone, epiandrosterone is also converted into 7α-hydroxyepiandrosterone by human CYP7B1. In human liver S9 fraction, when epiandrosterone is added, 7β-hydroxyepiandrosterone is formed.
In adult men treated with finasteride 5 mg daily for 4 months, lower plasma levels of many 5α-reduced steroids were observed, including DHT, allopregnanolone, androsterone, and epiandrosterone, demonstrating that pharmacological inhibition of 5α-reductase reduces circulating levels of epiandrosterone as well as of DHT.
5. Key Active Compounds and Mechanisms of Action
5.1 Androgenic Activity and Conversion to DHT
Epiandrosterone is only a weak androgen. Its primary pharmacological interest as a supplement ingredient derives from its role as a precursor: epiandrosterone, as a natural steroid hormone and metabolite of DHEA, serves as a precursor to the potent androgen hormone DHT, which influences male sexual characteristics, muscle mass, bone density, and libido. The conversion to DHT proceeds enzymatically through a two-step process involving the enzymes 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase in peripheral tissues.
5.2 Inhibition of the Pentose Phosphate Pathway (G6PD / NADPH)
A well-documented mechanism of epiandrosterone, established in basic science studies, involves its effects on cellular redox metabolism. Epiandrosterone is widely recognized to inhibit the pentose phosphate pathway and to decrease intracellular NADPH levels. A 17-ketosteroid, epiandrosterone, attenuates L-type Ca²⁺ currents (ICa-L) in cardiac myocytes and inhibits myocardial contractility. Because 17-ketosteroids are known to inhibit glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway, and to reduce intracellular NADPH levels, researchers hypothesized that inhibition of G6PD could be a novel signaling mechanism that inhibits ICa-L and, therefore, cardiac contractile function.
Inhibition of G6PD by DHEA has been shown to deplete cytosolic glutathione levels, thereby causing contractile dysfunction through dysregulation of Ca²⁺ homeostasis, and inhibition of G6PD by epiandrosterone has been shown to evoke suppression of ICa-L by decreasing the amplitude and shifting steady-state inactivation curve to hyperpolarizing potentials. Unlike epiandrosterone and dihydropyridine class of L-type Ca²⁺ channel blockers, a different inhibitor suppressed the channel activity by decreasing current amplitude without significantly affecting steady-state activation or inactivation state, suggesting that steroids exert their inhibitory effects through mechanisms in addition to G6PD-dependent redox changes.
The broader class of 17-ketosteroids, to which epiandrosterone belongs, shares this G6PD-inhibitory property. The 17-ketosteroids — including 17β-estradiol, testosterone, epiandrosterone, and DHEA — are known to inhibit glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway (PPP), and to reduce intracellular NADPH levels.
5.3 L-Type Calcium Channel Antagonism
Epiandrosterone may act as an L-type Ca²⁺ channel antagonist. This was demonstrated in vitro and in isolated organ preparations. The dehydroepiandrosterone metabolite epiandrosterone may act as an L-type Ca²⁺ channel antagonist with properties similar to known calcium channel blockers in that pharmacological class. The cardiac implications of this activity are discussed in the cardiovascular section below. This mechanism is established at the cellular/tissue level; its relevance to systemic pharmacology from oral supplementation in humans has not been determined.
5.4 Inhibition of G6PD and Antiviral Effects
Compounds related to epiandrosterone demonstrated an ability to inhibit mouse glucose-6-phosphate dehydrogenase activity, suggesting that epiandrosterone in its modified forms may hold promise as a potential inhibitor of this enzyme. This metabolic pathway also appears to underpin observed antiviral effects (see Section 7.4 below).
5.5 GABA Receptor Modulation
Epiandrosterone's structural isomer androsterone acts as a positive allosteric modulator of GABAA receptors and possesses anticonvulsant effects. Androsterone is known to be an inhibitory androstane neurosteroid, acting as a positive allosteric modulator of the GABAA receptor, and possesses anticonvulsant effects. Androsterone's 3β-isomer is epiandrosterone, and epiandrosterone has been reported to act as a negative modulator of GABAA receptors — the opposite of androsterone — an important pharmacological distinction between these two closely related isomers. This distinction, however, has been reported in supplement-review sources referencing primary literature; the specific primary peer-reviewed citation should be confirmed before clinical conclusions are drawn.
6. Body Systems and Areas of Research
6.1 Androgens and Steroid Hormone Axis
Epiandrosterone is primarily relevant as a node in the endogenous steroid network. DHEA is a multifunctional steroid with a wide range of biological effects and can be converted into various oxygenated metabolites, including epiandrosterone (EpiA), which also has significant biological roles in processes such as cancer, inflammation, and hormone regulation. Its conversion to DHT makes it relevant to all physiological and pathophysiological processes driven by DHT, including androgenetic alopecia, prostate biology, and anabolism in muscle and bone.
6.2 Cardiovascular System
The most mechanistically detailed research on epiandrosterone at the cellular level concerns its cardiovascular effects. As described above, epiandrosterone attenuates L-type Ca²⁺ currents in cardiac myocytes and inhibits myocardial contractility through an action involving inhibition of G6PD and reduction of intracellular NADPH levels. Research also documented vascular effects: at concentrations of 10 to 100 mM, epiandrosterone decreased left-ventricular developed pressure (LVDP) and myocardial contraction rate dose-dependently; it also increased coronary perfusion pressure in isolated hearts, down-regulated levels of myocardial NADPH and nitrite, and relaxed rat aortic rings in a dose-dependent manner.
Importance of context: These effects were demonstrated at supraphysiological concentrations in isolated heart and aortic ring preparations. Whether oral supplementation in humans produces cardiac concentrations anywhere near those used in these experiments is unknown. All cardiac evidence is preclinical (in vitro and animal); no controlled human clinical data exist for these endpoints.
6.3 Neurological System and Neuroprotection
Epiandrosterone's hydroxylated metabolite, 7β-hydroxy-epiandrosterone (7β-OH-EpiA), has attracted research interest for neuroprotection. 7β-hydroxy-epiandrosterone (7β-OH-EpiA) is an endogenous androgen metabolite that has been shown to exert neuroprotective, anti-inflammatory, and anti-estrogenic effects. Data demonstrate that 7-hydroxylation of steroids confers neuroprotective efficacy, and that 7β-OH-epiandrosterone represents a novel class of neuroprotective compounds. The neuroprotective effects were shown both in vivo and in vitro in animal models of ischemic neuronal damage, as described in peer-reviewed research.
Limitation: These findings relate to a downstream metabolite (7β-OH-EpiA) rather than to epiandrosterone itself, and the evidence is predominantly preclinical. No published randomized controlled trials in humans have evaluated epiandrosterone supplementation for neuroprotective outcomes.
6.4 Inflammatory Pathways
7β-Hydroxy-epiandrosterone (7β-OH-EpiA), an endogenous androgenic derivative of DHEA, has previously been shown to exert anti-inflammatory action in vitro and in vivo via a shift from prostaglandin E2 (PGE2) to 15-deoxy-Δ12,14-PGJ2 production. This modulation in prostaglandin production was obtained with low concentrations of 7β-OH-EpiA (1–100 nM) and suggested that it might act through a specific receptor. Again, this evidence is for the 7β-hydroxy metabolite and is based on in vitro and animal studies.
6.5 Anti-Estrogenic and Oncological Research
7β-OH-EpiA exerted anti-estrogenic effects in MCF-7 and MDA-MB-231 breast cancer cell lines, associated with cell proliferation inhibition and cell cycle arrest; transactivation and proliferation assays indicated that 7β-OH-EpiA interacted with ERβ, and data also suggested that it may act through the membrane GPR30 receptor. These results support that this androgenic steroid acts as an anti-estrogenic compound, and this represents the first evidence that low doses of an androgenic steroid exert antiproliferative effects in these mammary cancer cells.
Limitation: All anti-cancer evidence for 7β-OH-EpiA is from cell-line (in vitro) studies. No clinical trials in cancer patients have been conducted. These data should not be interpreted as evidence of clinical anticancer efficacy of epiandrosterone supplementation.
6.6 Male Fertility
Levels of 7β-OH-EpiA, an endogenous androgen metabolite that exerts neuroprotective, anti-inflammatory, and anti-estrogenic effects, were measured in plasma and seminal plasma using an isotope dilution ultra-high performance liquid chromatography–mass spectrometry method. Levels of 7β-OH-EpiA were measured in 191 men with different degrees of infertility. The study (Vitku et al., 2018, published in Physiological Research) examined associations between circulating 7β-OH-EpiA and sperm quality, but the published abstract did not report positive therapeutic findings. This area is exploratory; no supplementation trials have been conducted.
6.7 Antiviral Activity
The in vitro antiviral activity of DHEA, epiandrosterone (EA), and 16 synthetic derivatives against Junin virus (JUNV) replication in Vero cells was studied; DHEA and EA caused selective inhibition of the replication of JUNV and other members of the Arenaviridae family, such as Pichinde virus and Tacaribe virus. The compounds were not virucidal to cell-free JUNV, and the impairment of viral replication was not due to inhibitory effects on virus adsorption or internalization; rather, an inhibitory effect on JUNV protein synthesis and both intracellular and extracellular virus production was demonstrated. Some compounds obtained from epiandrosterone by chemical synthesis showed selectivity indices higher than ribavirin, the only antiviral compound that has shown partial efficacy against Junin virus in clinical contexts (Acosta et al., 2008, published in Steroids).
Limitation: This is entirely in vitro research. No human clinical trials have evaluated epiandrosterone or its derivatives for antiviral therapy.
7. Scientific Evidence by Area of Use
7.1 Body Composition and Athletic Performance
The most prominent marketed use of epiandrosterone as a supplement is for promoting lean muscle mass, reducing body fat, and enhancing athletic performance, claims premised on its conversion to DHT. The evidence base for these claims as applied to oral supplementation in healthy humans is extremely thin.
There are no high-quality randomized controlled trials (RCTs) in healthy adults showing that oral epiandrosterone improves strength, hypertrophy, or fat loss beyond what structured training and nutrition achieve alone. It may influence body composition or training indirectly via weak androgenic activity, but robust human data for supplementation are lacking.
Epiandrosterone is real biology — but as an endogenous weak androgen and metabolite, not a clinically validated performance enhancer. Understanding it as one node in a complex steroid network helps set expectations: local effects are plausible; strong, consistent whole-body effects in healthy trainees are unproven.
The theoretical basis for body composition effects rests on DHT physiology: epiandrosterone's conversion to DHT contributes to its androgenic effects; DHT is involved in the development of male sexual characteristics and is important for maintaining muscle mass, bone density, and libido, and epiandrosterone's conversion to DHT may include promoting lean muscle growth and enhancing strength. However, these are mechanistic extrapolations, not outcomes demonstrated in supplementation trials.
Evidence strength: Very weak. No adequate RCTs exist as of the available literature. All performance-related claims are extrapolations from preclinical data and DHT biology.
7.2 Cardiovascular Effects
The available research at the cellular and organ-preparation level suggests epiandrosterone acts as an L-type calcium channel antagonist and G6PD inhibitor in cardiac tissue, effects that would be expected to reduce cardiac contractility. Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility. This was established in studies using isolated animal heart preparations and cardiac myocyte patch-clamp electrophysiology. No human clinical studies have tested cardiovascular endpoints of supplementation.
Evidence strength: Preclinical only (in vitro and animal). No human data.
7.3 Neuroprotection
Research on 7β-hydroxylated metabolites of epiandrosterone (formed in the liver and other tissues when epiandrosterone is the substrate) has shown neuroprotective properties in ischemia models. 7β-hydroxy-epiandrosterone, an endogenous androgenic derivative of DHEA, has been shown to exert anti-inflammatory action in vitro and in vivo via a shift from prostaglandin E2 (PGE2) to 15-deoxy-Δ12,14-PGJ2 production. Some sources note early-stage Phase II clinical trial planning for 7β-OH-EpiA in Alzheimer's disease, but no trial results have been published in the available literature.
Evidence strength: Preliminary preclinical evidence for a downstream metabolite. Not established for epiandrosterone itself in humans.
7.4 Antiviral Activity
As described in Section 6.7, epiandrosterone and synthetic derivatives demonstrated in vitro inhibitory activity against Arenaviruses. The mechanism involved inhibition of viral protein synthesis and viral production, not direct virucidal activity. A partial inhibitory action on cell surface expression of JUNV glycoprotein G1 was also detected in DHEA- and EA-treated cultures.
Evidence strength: In vitro only. No animal in vivo or human clinical data.
7.5 G6PD Inhibition and Metabolic Research
3β-alkanesulfonate derivatives of epiandrosterone demonstrated the ability to inhibit mouse glucose-6-phosphate dehydrogenase activity; further research into the precise mechanism and efficacy of these inhibitors could pave the way for development of novel therapeutic agents targeting glucose-6-phosphate dehydrogenase activity. G6PD inhibition is a recognized pharmacological target in conditions of oxidative stress and in some cancers, but this remains exploratory and no human clinical work with epiandrosterone or its synthetic derivatives for this purpose has been published.
Evidence strength: Preliminary, in vitro and animal pharmacology only.
7.6 Sports Doping Detection
Epiandrosterone has been studied as a potential urinary marker for exogenous testosterone use rather than as a therapeutic agent. Epiandrosterone has been identified as a potential long-term marker for the abuse of testosterone; its applicability as a marker has been evaluated through administration studies involving transdermal, intramuscular, and subcutaneous testosterone. Results indicate that epiandrosterone sulfate is less effective than conventionally used target compounds for detecting low-dose testosterone application, particularly with transdermal gel administration; while it showed greater diagnostic potential with intramuscular administration, it did not significantly extend the detection window beyond that of conventional target compounds, and its responsiveness to higher-dose administration varied based on the magnitude of the dose, indicating limited utility as a marker for low-dose testosterone administration.
8. Regulatory and Legal Status
In the United States, epiandrosterone is a Schedule III controlled substance that is not legal for use in supplements, but it is still found in some supplement products. It is also banned by the World Anti-Doping Agency (WADA). It is listed as an anabolic agent on the World Anti-Doping Agency Prohibited List; use can trigger anti-doping violations.
The WADA Prohibited List is a mandatory International Standard under the World Anti-Doping Code and is updated every year following an extensive consultation process; the 2026 Prohibited List came into effect on 1 January 2026. Athletes are strictly responsible for any prohibited substance found in their body; under World Athletics Anti-Doping Rules, the presence or use of a prohibited substance constitutes an anti-doping rule violation, regardless of intent.
The scheduling of epiandrosterone as a controlled substance in the United States flows from the Designer Anabolic Steroid Control Act of 2014 (DASCA), which extended Schedule III status to a broad range of prohormones and anabolic steroid precursors. Its classification as an anabolic steroid for regulatory purposes overrides its endogenous and naturally occurring character.
9. Dosage Forms and Dosages Reported in Sources
Epiandrosterone is marketed in oral capsule and tablet forms, as well as in topical (transdermal) creams and gels designed to bypass first-pass hepatic metabolism. No standardized or clinically validated dosage exists, because no adequate human clinical trials of oral epiandrosterone supplementation for any indication have been conducted and published in the peer-reviewed literature.
No evidence-based oral dose is established for humans; outside clinical research, a prudent choice is 0 mg per day, as characterized in a rigorously referenced supplement analysis.
The range of doses observed in marketed supplement products (not established in clinical trials) has generally been reported at 50–250 mg per day by retail sources, but these figures are not drawn from peer-reviewed dosage-finding studies and should not be taken as evidence-based guidance. Doses used in in vitro cardiac experiments (10–100 mM) are pharmacologically irrelevant to oral supplementation; they were employed in isolated tissue preparations to characterize mechanistic responses.
10. Safety Considerations
10.1 Androgenic Side Effects
Because epiandrosterone converts to DHT, it carries all the known androgenic side effects associated with elevated DHT. When taken by mouth, epiandrosterone is possibly unsafe for most people; side effects include infertility, behavioral changes, and hair loss; it might also lead to liver damage and heart disease. Androgenetic alopecia is a well-established consequence of elevated DHT levels in genetically susceptible individuals: the same mechanism by which epiandrosterone is marketed for anabolic effects (DHT conversion) is what drives DHT-mediated hair follicle miniaturization.
10.2 Cardiovascular Concerns
The established laboratory finding that epiandrosterone blocks L-type calcium channels and inhibits myocardial contractility in cardiac tissue preparations constitutes a theoretical cardiovascular safety concern. Epiandrosterone might lead to liver damage and heart disease. In experimental models, epiandrosterone at concentrations of 10 to 100 mM decreased left-ventricular developed pressure and myocardial contraction rate dose-dependently, increased coronary perfusion pressure, down-regulated myocardial NADPH and nitrite levels, and relaxed rat aortic rings in a dose-dependent manner. Whether these effects translate to clinically significant cardiovascular risk from oral supplementation at real-world doses has not been established in controlled human studies.
10.3 Endocrine Disruption
Because epiandrosterone is an endogenous steroid that influences the hypothalamic-pituitary-gonadal (HPG) axis via its downstream conversion to DHT, exogenous supplementation carries a risk of suppressing endogenous testosterone production via negative feedback, potentially causing testicular atrophy, reduced sperm production, and a withdrawal syndrome upon cessation. These effects are common to anabolic steroid-class compounds generally and are expected to apply to epiandrosterone, though specific clinical studies on its HPG-axis suppression in humans are not available in the published literature consulted.
10.4 Finasteride Interaction
Because 5α-reductase converts DHEA to epiandrosterone, pharmacological inhibition of 5α-reductase with finasteride 5 mg daily for 4 months in adult men results in lower plasma levels of many 5α-reduced steroids, including epiandrosterone. Conversely, exogenous epiandrosterone would be expected to compete with and potentially partially override the effects of 5α-reductase inhibitors on DHT biosynthesis pathways, though this specific pharmacokinetic interaction has not been formally studied. Use of epiandrosterone alongside 5α-reductase inhibitors (finasteride, dutasteride) intended to manage androgenetic alopecia or benign prostatic hyperplasia would be expected to counteract those drugs' therapeutic mechanisms.
10.5 G6PD Deficiency Interaction
Epiandrosterone is widely recognized to inhibit the pentose phosphate pathway and to decrease intracellular NADPH levels. In individuals with pre-existing G6PD deficiency — an inherited condition affecting several hundred million people worldwide — additional inhibition of this enzyme by epiandrosterone could in theory exacerbate oxidative stress in red blood cells and other tissues. This interaction has not been formally studied in supplementation contexts.
10.6 Hormone-Sensitive Conditions
Given its conversion to DHT, epiandrosterone would be contraindicated in individuals with hormone-sensitive conditions, including prostate cancer, benign prostatic hyperplasia, breast cancer, and androgenetic alopecia in which DHT is a driving factor. No controlled clinical safety data exist specific to epiandrosterone in these populations.
10.7 Supplement Contamination and Legal Risk
Epiandrosterone's classification as both a Schedule III controlled substance in the United States and a WADA-prohibited anabolic agent means that products containing it (whether labeled or as an undisclosed contaminant) create legal liability and risk of anti-doping violations. In the United States, epiandrosterone is a Schedule III controlled substance not legal for use in supplements, but it is still found in some supplement products.
11. Summary of Evidence Strength
- Mechanism of action (G6PD inhibition, L-type Ca²⁺ channel antagonism): Well-characterized at the cellular and tissue level in preclinical models. Established scientific finding, not extrapolable to clinical benefit without human trials.
- Conversion to DHT (endocrine role): Well-established biochemically; confirmed in enzymatic and metabolic studies. Clinical significance of exogenous supplementation is not documented in RCTs.
- Body composition and athletic performance: No adequate RCTs. Evidence is absent. Claims are theoretical extrapolations from DHT biology.
- Neuroprotection: Preliminary preclinical evidence for the 7β-hydroxylated metabolite, not for epiandrosterone itself. No human data.
- Anti-inflammatory effects: Demonstrated in vitro and in animal models for 7β-OH-EpiA. No human clinical data.
- Antiviral activity: In vitro only, against Arenaviruses. No human data.
- Doping marker utility: Limited; less effective than established urinary markers for detecting low-dose testosterone administration.
References
Go back